Elevation Oncology (Elevation Oncology) Scaled Net Operating Assets : 0.03 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Elevation Oncology's operating assets for the quarter that ended in Mar. 2024 was $4.91 Mil. Elevation Oncology's operating liabilities for the quarter that ended in Mar. 2024 was $2.33 Mil. Elevation Oncology's Total Assets for the quarter that ended in Dec. 2023 was $89.09 Mil. Therefore, Elevation Oncology's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.03.

Elevation Oncology Scaled Net Operating Assets Historical Data

The historical data trend for Elevation Oncology's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elevation Oncology Scaled Net Operating Assets Chart

Elevation Oncology Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Scaled Net Operating Assets

-3.98

-53.54

-0.07

-0.08

0.02

Elevation Oncology Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial												-0.11	-0.08	-0.02	0.02	0.03

Competitive Comparison of Elevation Oncology's Scaled Net Operating Assets

For the Biotechnology subindustry, Elevation Oncology's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elevation Oncology's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's Scaled Net Operating Assets falls into.

Elevation Oncology Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Elevation Oncology's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(5.984	-	4.145)	/	94.161
=	0.02

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	89.091	-	83.107
=	5.984

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	34.282	-	30.137	-	0
=	4.145

Elevation Oncology's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(4.91	-	2.334)	/	89.091
=	0.03

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	108.961	-	104.051
=	4.91

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	33.143	-	30.809	-	0
=	2.334

Elevation Oncology Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Elevation Oncology (Elevation Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106

Website

https://www.elevationoncology.com

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Executives

Tammy Furlong	officer: CHIEF FINANCIAL OFFICER	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen	officer: Chief Medical Officer	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff	other: Managing Member	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	director, other: Managing Member	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin	director	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106